These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24401320)

  • 1. Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey: author's reply.
    Oncel MY; Alyamaç-Dizdar E; Erdeve O; Oğuz S; Dilmen U
    Turk J Pediatr; 2013; 55(5):568. PubMed ID: 24401320
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey.
    Paes B; Lanctôt K
    Turk J Pediatr; 2013; 55(5):564-7. PubMed ID: 24382545
    [No Abstract]   [Full Text] [Related]  

  • 3. Palivizumab prophylaxis during respiratory syncytial virus outbreak in neonatal intensive care unit: author's reply.
    Oncel MY; Dizdar EA; Dilmen U
    Turk J Pediatr; 2013; 55(2):239. PubMed ID: 24205516
    [No Abstract]   [Full Text] [Related]  

  • 4. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
    Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palivizumab prophylaxis during respiratory syncytial virus outbreak in the neonatal intensive care unit.
    Alan S; Cakır U; Erdeve O; Atasay B; Arsan S
    Turk J Pediatr; 2013; 55(2):237-8. PubMed ID: 24192692
    [No Abstract]   [Full Text] [Related]  

  • 6. Respiratory syncytial virus prophylaxis reduces chronic respiratory morbidity in prematurely born infants.
    Greenough A
    Evid Based Med; 2014 Apr; 19(2):65. PubMed ID: 24142143
    [No Abstract]   [Full Text] [Related]  

  • 7. Respiratory syncytial virus infection is linked to recurrent wheezing in healthy premature infants.
    Escobar GJ
    J Pediatr; 2013 Nov; 163(5):1531. PubMed ID: 24160662
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.
    Salinas-Escudero G; Martínez-Valverde S; Reyes-López A; Garduño-Espinosa J; Muñoz-Hernández O; Granados-García V; Rely K
    Salud Publica Mex; 2012; 54(1):47-59. PubMed ID: 22286828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody against RSV helps prevent wheeze in infants.
    BMJ; 2013 May; 346():f3089. PubMed ID: 23678095
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
    Neovius K; Buesch K; Sandström K; Neovius M
    Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
    Checchia PA; Nalysnyk L; Fernandes AW; Mahadevia PJ; Xu Y; Fahrbach K; Welliver RC
    Pediatr Crit Care Med; 2011 Sep; 12(5):580-8. PubMed ID: 21200358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus and recurrent wheeze.
    Blanken MO; Rovers MM; Bont L;
    N Engl J Med; 2013 Aug; 369(8):782-3. PubMed ID: 23964947
    [No Abstract]   [Full Text] [Related]  

  • 13. Respiratory syncytial virus and recurrent wheeze.
    Brand PL
    N Engl J Med; 2013 Aug; 369(8):782. PubMed ID: 23964948
    [No Abstract]   [Full Text] [Related]  

  • 14. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab prophylaxis: does it have any influence on the growth and development of the infants?
    Tavsu I; Gursoy T; Dirman S; Erbil N; Ovali F
    Am J Perinatol; 2014 Sep; 31(8):667-72. PubMed ID: 24022378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?
    Elnazir B; Oni O; Hassan T; Greally P; Paes B
    J Paediatr Child Health; 2012 Nov; 48(11):1033-8. PubMed ID: 23126393
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
    Robinson JL
    Curr Med Res Opin; 2009 Jul; 25(7):1631-2; author reply 1632-3. PubMed ID: 19480611
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.